Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2019 Results (n=62) assessing efficacy and safety of carfilzomib and irinotecan in small cell lung cancer patients, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 31 Aug 2018 Biomarkers information updated
- 03 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.